A Study to Investigate the Efficacy and Safety of Eribulin in Korean Breast Cancer Participants

Eisai logo

Eisai

Status

Completed

Conditions

Locally Advanced or Metastatic Breast Cancer

Treatments

Drug: Eribulin mesylate

Study type

Observational

Funder types

Industry

Identifiers

NCT03437083
E7389-M082-602

Details and patient eligibility

About

The primary objective of the study is to observe efficacy in terms of progression-free survival rate at 6 months in eribulin-treated breast cancer participants retrospectively.

Enrollment

340 patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Confirmed diagnosis of locally advanced or metastatic breast cancer
  • Participants who were treated with Eribulin between 01 June, 2014 and 31 December, 2016

Exclusion criteria

Not applicable

Trial design

340 participants in 1 patient group

Eribulin
Description:
Eribulin was administered at a dose of 1.4 milligrams per meters squared (mg/m^2) (as eribulin 1.23 mg/m^2) by a 2- to 5-minute intravenous infusion or as a diluted solution on Day 1 and Day 8 every 21 days.
Treatment:
Drug: Eribulin mesylate

Trial contacts and locations

14

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems